Protalix BioTherapeutics announced a net income of $18.3 million for Q1 2026, a significant turnaround from a loss in the same period last year. This was largely due to a $25 million milestone payment from partner Chiesi following European Commission approval of Elfabrio's new dosing regimen for Fabry disease. The company reaffirmed its 2026 revenue guidance of $78-$83 million, supported by ongoing commercial execution and clinical progress, including the Phase 2 trial of PRX-115 for uncontrolled gout with top-line results expected in late 2027. Protalix maintains a strong cash position of $51 million to fund operations and growth initiatives focused on rare diseases.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
